JPS6154451A - 群特異性を有するアフイニテイクロマトグラフイ用ゲルおよびその製法 - Google Patents
群特異性を有するアフイニテイクロマトグラフイ用ゲルおよびその製法Info
- Publication number
- JPS6154451A JPS6154451A JP59177348A JP17734884A JPS6154451A JP S6154451 A JPS6154451 A JP S6154451A JP 59177348 A JP59177348 A JP 59177348A JP 17734884 A JP17734884 A JP 17734884A JP S6154451 A JPS6154451 A JP S6154451A
- Authority
- JP
- Japan
- Prior art keywords
- gel
- affinity chromatography
- sulfate
- virus
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001042 affinity chromatography Methods 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 15
- 239000005017 polysaccharide Substances 0.000 claims abstract description 15
- 150000004676 glycans Chemical class 0.000 claims abstract description 13
- 239000007787 solid Substances 0.000 claims abstract description 10
- 150000001408 amides Chemical class 0.000 claims abstract description 7
- 150000001412 amines Chemical class 0.000 claims abstract description 7
- 239000003513 alkali Substances 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 27
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 22
- 229920000936 Agarose Polymers 0.000 claims description 13
- -1 sulfuric acid ester Chemical class 0.000 claims description 11
- 229920002678 cellulose Polymers 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 3
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 claims description 2
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 24
- 108090000623 proteins and genes Proteins 0.000 abstract description 24
- 241000700605 Viruses Species 0.000 abstract description 19
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract description 15
- 239000002994 raw material Substances 0.000 abstract description 12
- 238000006243 chemical reaction Methods 0.000 abstract description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 abstract description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 abstract description 6
- 239000008187 granular material Substances 0.000 abstract description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 238000004440 column chromatography Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 3
- 238000007670 refining Methods 0.000 abstract 2
- 229940086542 triethylamine Drugs 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- 239000000872 buffer Substances 0.000 description 18
- 238000000746 purification Methods 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000010828 elution Methods 0.000 description 12
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 10
- 229920000669 heparin Polymers 0.000 description 10
- 229960002897 heparin Drugs 0.000 description 10
- 238000001179 sorption measurement Methods 0.000 description 10
- 241000588832 Bordetella pertussis Species 0.000 description 9
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 9
- 235000011613 Pinus brutia Nutrition 0.000 description 9
- 241000018646 Pinus brutia Species 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000007853 buffer solution Substances 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 229920001499 Heparinoid Polymers 0.000 description 5
- 241000710842 Japanese encephalitis virus Species 0.000 description 5
- 238000011067 equilibration Methods 0.000 description 5
- 239000002554 heparinoid Substances 0.000 description 5
- 230000001766 physiological effect Effects 0.000 description 5
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108090000935 Antithrombin III Proteins 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011403 purification operation Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- DEWLEGDTCGBNGU-UHFFFAOYSA-N 1,3-dichloropropan-2-ol Chemical compound ClCC(O)CCl DEWLEGDTCGBNGU-UHFFFAOYSA-N 0.000 description 1
- 102100034088 40S ribosomal protein S4, X isoform Human genes 0.000 description 1
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000732165 Homo sapiens 40S ribosomal protein S4, X isoform Proteins 0.000 description 1
- 241000285721 Ibaraki virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical compound OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012374 esterification agent Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- PZLXYMQOCNYUIO-UHFFFAOYSA-N lithium;hydrochloride Chemical compound [Li].Cl PZLXYMQOCNYUIO-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- XZEUAXYWNKYKPL-URLMMPGGSA-N ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- UFWWAKOWSBGGCP-UHFFFAOYSA-N pyridine;sulfurochloridic acid Chemical compound OS(Cl)(=O)=O.C1=CC=NC=C1 UFWWAKOWSBGGCP-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/291—Gel sorbents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
- B01J2220/54—Sorbents specially adapted for analytical or investigative chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59177348A JPS6154451A (ja) | 1984-08-24 | 1984-08-24 | 群特異性を有するアフイニテイクロマトグラフイ用ゲルおよびその製法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59177348A JPS6154451A (ja) | 1984-08-24 | 1984-08-24 | 群特異性を有するアフイニテイクロマトグラフイ用ゲルおよびその製法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6154451A true JPS6154451A (ja) | 1986-03-18 |
| JPH0423752B2 JPH0423752B2 (en, 2012) | 1992-04-23 |
Family
ID=16029394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59177348A Granted JPS6154451A (ja) | 1984-08-24 | 1984-08-24 | 群特異性を有するアフイニテイクロマトグラフイ用ゲルおよびその製法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6154451A (en, 2012) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63209750A (ja) * | 1987-02-25 | 1988-08-31 | Kanegafuchi Chem Ind Co Ltd | 血液凝固第８因子精製用吸着体およびそれを用いた血液凝固第８因子の精製法 |
| WO2000068398A1 (fr) * | 1999-05-11 | 2000-11-16 | Institut Pasteur De Lille | Procede de purification par affinite |
| JP2002500088A (ja) * | 1998-01-12 | 2002-01-08 | ハー マジェスティ イン ライト オブ カナダ アズ リプレゼンティッド バイ ザ ミニスター オブ アグリカルチャー アンド アグリ−フード カナダ | 非極性抽出物の単離、回収及び精製方法 |
| GB2429708A (en) * | 2005-09-01 | 2007-03-07 | Chisso Corp | Spherical sulphated cellulose |
| WO2008078795A1 (ja) * | 2006-12-26 | 2008-07-03 | Chisso Corporation | 架橋セルロース誘導体の金属塩 |
| WO2008078797A1 (ja) * | 2006-12-26 | 2008-07-03 | Otsuka Pharmaceutical Factory, Inc. | ナトリウム吸収阻害剤、カリウム吸収阻害剤およびリン吸収阻害剤、並びにそれを含む予防剤、治療剤および食品 |
| GB2465301A (en) * | 2005-09-01 | 2010-05-19 | Chisso Corp | Spherical sulphated cellulose |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5332090B2 (ja) * | 2005-09-01 | 2013-11-06 | Ｊｎｃ株式会社 | 球状硫酸化セルロース及びその製造方法 |
-
1984
- 1984-08-24 JP JP59177348A patent/JPS6154451A/ja active Granted
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63209750A (ja) * | 1987-02-25 | 1988-08-31 | Kanegafuchi Chem Ind Co Ltd | 血液凝固第８因子精製用吸着体およびそれを用いた血液凝固第８因子の精製法 |
| JP2002500088A (ja) * | 1998-01-12 | 2002-01-08 | ハー マジェスティ イン ライト オブ カナダ アズ リプレゼンティッド バイ ザ ミニスター オブ アグリカルチャー アンド アグリ−フード カナダ | 非極性抽出物の単離、回収及び精製方法 |
| WO2000068398A1 (fr) * | 1999-05-11 | 2000-11-16 | Institut Pasteur De Lille | Procede de purification par affinite |
| FR2793492A1 (fr) * | 1999-05-11 | 2000-11-17 | Pasteur Institut | Nouveau procede de purification par affinite |
| GB2465301B (en) * | 2005-09-01 | 2010-06-30 | Chisso Corp | Spherical sulfated cellulose |
| GB2465301A (en) * | 2005-09-01 | 2010-05-19 | Chisso Corp | Spherical sulphated cellulose |
| GB2429708B (en) * | 2005-09-01 | 2010-06-02 | Chisso Corp | Spherical sulfated cellulose |
| GB2429708A (en) * | 2005-09-01 | 2007-03-07 | Chisso Corp | Spherical sulphated cellulose |
| WO2008078795A1 (ja) * | 2006-12-26 | 2008-07-03 | Chisso Corporation | 架橋セルロース誘導体の金属塩 |
| WO2008078797A1 (ja) * | 2006-12-26 | 2008-07-03 | Otsuka Pharmaceutical Factory, Inc. | ナトリウム吸収阻害剤、カリウム吸収阻害剤およびリン吸収阻害剤、並びにそれを含む予防剤、治療剤および食品 |
| JP5277964B2 (ja) * | 2006-12-26 | 2013-08-28 | Ｊｎｃ株式会社 | 架橋セルロース誘導体の金属塩 |
| JP5277965B2 (ja) * | 2006-12-26 | 2013-08-28 | Ｊｎｃ株式会社 | ナトリウム吸収阻害剤、カリウム吸収阻害剤およびリン吸収阻害剤、並びにそれを含む予防剤、治療剤および食品 |
| US8779119B2 (en) | 2006-12-26 | 2014-07-15 | Jnc Corporation | Metal salt of crosslinked cellulose derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0423752B2 (en, 2012) | 1992-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920009733B1 (ko) | 인플루엔자 바이러스의 정제방법 | |
| KR880002586B1 (ko) | B형 간염 바이러스 표면 항원의 정제방법 | |
| CA1251398A (en) | Method for purification of rabic virus | |
| JPH0724723B2 (ja) | 硫酸化された非炭水化物ゲルマトリツクス吸着剤 | |
| KR890001927B1 (ko) | 섬유질 헤마글루티닌의 정제방법 | |
| Bessler et al. | A bacteriophage-induced depolymerase active on Klebsiella K11 capsular polysaccharide | |
| JPS6147185A (ja) | 日本脳炎ウイルスの精製方法 | |
| JPS6356501A (ja) | アフイニテイークロマトグラフイー用カラム充填剤及びその製造方法 | |
| JPS6154451A (ja) | 群特異性を有するアフイニテイクロマトグラフイ用ゲルおよびその製法 | |
| JPS58201794A (ja) | ヒトインターフェロンβの濃縮精製法 | |
| JPS6154450A (ja) | 群特異性を有するアフイニテイクロマトグラフイ用ゲルおよびその製造法 | |
| KR920009730B1 (ko) | 백일해 성분 백신 및 백일해 항원, 디프테리아 톡소이드 및 파상풍 톡소이드의 혼합백신의 제조방법 | |
| JP2511500B2 (ja) | 胎盤組織タンパク質ｐｐ▲下４▼の精製法 | |
| EP0170162B1 (en) | Method for the purification of leukocytosis-promoting factor haemagglutinin | |
| JPS59164727A (ja) | Ｂ型肝炎ウイルス表面抗原の精製方法 | |
| US20030148488A1 (en) | Method for the production of pure virally inactivated butyrylcholinesterase | |
| JPS6156133A (ja) | 発熱物質の除去方法 | |
| JPH07121876B2 (ja) | 静注用免疫グロブリンの製法 | |
| JPS641446B2 (en, 2012) | ||
| JP2627186B2 (ja) | レトロウイルスの精製方法 | |
| RU1776415C (ru) | Способ очистки поверхностного антигена вируса гепатита В (НВ @ А @ ) | |
| JPS641447B2 (en, 2012) | ||
| JPS6241691B2 (en, 2012) | ||
| JPH06107694A (ja) | 平滑筋細胞由来遊走因子 | |
| JPS641448B2 (en, 2012) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |